Anidulafungin versus fluconazole for invasive candidiasis. - Wikidata - wikimedia - TriplyDB

Anidulafungin versus fluconazole for invasive candidiasis.

Anidulafungin versus fluconazole for invasive candidiasis.

http://www.wikidata.org/entity/Q34580316

about

Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit Invasive candidiasis as a cause of sepsis in the critically ill patient Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections Role of isavuconazole in the treatment of invasive fungal infections Clinical perspectives on echinocandin resistance among Candida species Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!Echinocandin resistance: an emerging clinical problem?Intensive care medicine research agenda on invasive fungal infection in critically ill patients.Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the Prospective Antifungal Therapy Alliance registry, a multicenter, observational study Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination.Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data.ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients Safety and Efficacy of Anidulafungin for Fungal Infection in Patients With Liver Dysfunction or Multiorgan Failure Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America Invasive fungal infections in transplant recipients Novel FKS mutations associated with echinocandin resistance in Candida species.Clinical factors associated with a Candida albicans Germ Tube Antibody positive test in Intensive Care Unit patients In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection.Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.Fungal infections in transplant and oncology patients.Breakthrough invasive candidiasis in patients on micafungin.Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.Echinocandins: the newest class of antifungals.Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Canadian clinical practice guidelines for invasive candidiasis in adults.Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period Antifungal clinical trials and guidelines: what we know and do not know Invasive fungal infections in solid organ transplant recipients.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study Clinical hepatotoxicity associated with antifungal agents.Pharmacokinetics and tissue distribution of anidulafungin in rats.Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial Study on the effect of neem (Azadirachta indica A. juss) leaf extract on the growth of Aspergillus parasiticus and production of aflatoxin by it at different incubation times.Micafungin compared with caspofungin for the treatment of febrile episodes in neutropenic patients with hematological malignancies: A retrospective study.Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.Management bundles for candidaemia: the impact of compliance on clinical outcomes.Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.

P2860

Q21194915-5E9DBBE6-6705-4DE9-888F-002D6A3875E8 Q22305429-E5820557-DD94-4C68-B554-17B6327B8ADD Q24239978-3B995BB8-1C4D-4CDA-BB9F-377186A3896B Q26740837-2EC9AEF2-635C-43B4-9CA4-1775303387EC Q28082538-DAAF2FF5-A51A-41C4-8741-B1E3E6FD1C07 Q28082570-BF55F969-D164-4C97-A581-F9EB8DD95038 Q28544739-1400CB18-FB25-4895-BB6E-86A944C3535D Q30235457-58E943CB-1D3D-4A58-90E5-54210A266E62 Q30781344-04478CD1-2952-4A66-9D29-4A1DA4011ABD Q33490772-1102AF40-2A3F-4ADA-8AE0-A0C45D7C4187 Q33559503-1A53712E-0D26-46F5-8B14-054827E19B51 Q33573788-051E3CC8-78EC-48BD-A487-68D576B7F4E8 Q33629353-1ACE0A9A-59EF-4728-A46B-164253EE9729 Q33688646-532915DE-800F-48A2-8EAB-841D2E47219C Q33695215-25539F1B-9472-4CF0-AF8F-C94B4555FC3A Q33826330-5C5B7CF9-A3D1-4740-B1F7-12F1F66E3F23 Q33841485-9B5156DF-5AEF-4BE0-A330-B6BE9BD434C3 Q33876423-DC17B74F-0622-425B-8A76-1A10258060A2 Q33876645-EE45976D-86B4-4DF8-89B1-69E54DE8BBB5 Q33891810-AC7FF283-327D-4339-8589-6AF73B2A2451 Q33896940-B973AADB-E7B6-4B39-B705-DD60094E28B7 Q33963538-74F04903-1EDE-4AC0-A20A-A5D0A6D14583 Q34006585-11E904AC-9F88-437A-B09A-FEB295768136 Q34019188-D4A4EAB6-0768-47BC-9FC8-803A1B02B1EF Q34036214-F4C9170C-8FB6-4E81-BA6B-96D61CAE8F3F Q34212799-ED0482F7-DAF0-4B50-BFE9-8B0E098566C8 Q34237335-57A10562-99D3-4D6B-9008-455FCDD0A4F2 Q34252030-B545315F-37CF-4FE2-ACF6-2F38072995A6 Q34400255-47FCF480-1C69-4D82-8D1E-BD495856F516 Q34461693-931A1DD1-94B9-411F-9082-BA9282D12D64 Q34505582-3F43C87F-FF69-4DD0-83F1-7C2D3A554695 Q34543097-934E441E-1D37-4032-B244-063971BC54F4 Q34546811-264C5B87-DD27-4DA4-B7E2-5A7742CA7AF1 Q34591184-CC6ACC29-892B-4025-B7A4-2851E4DC6E4D Q34724039-5BEFAA20-A728-4822-9C55-8DD7C933A467 Q34724824-A00B4651-7F67-4489-AFA2-D8B3E0BD81D5 Q34775518-8538D787-384B-4BA9-9983-A48E368B0230 Q34900399-BF0F786E-0ADF-4BE4-8034-585792895490 Q34920621-52DA770A-4998-4FC6-B044-4CDCE3489B0B Q34933267-7C9134C7-0170-420E-A781-4F16BDED163B

P2860

Anidulafungin versus fluconazole for invasive candidiasis.

http://www.wikidata.org/entity/Q34580316

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Anidulafungin versus fluconazole for invasive candidiasis.

@ast

Anidulafungin versus fluconazole for invasive candidiasis.

@en

Anidulafungin versus fluconazole for invasive candidiasis.

@nl

type

label

Anidulafungin versus fluconazole for invasive candidiasis.

@ast

Anidulafungin versus fluconazole for invasive candidiasis.

@en

Anidulafungin versus fluconazole for invasive candidiasis.

@nl

prefLabel

Anidulafungin versus fluconazole for invasive candidiasis.

@ast

Anidulafungin versus fluconazole for invasive candidiasis.

@en

Anidulafungin versus fluconazole for invasive candidiasis.

@nl

P1433

Q34580316-8F7BD164-9E46-479F-B632-800B9EA84353

P1476

Q34580316-527CFE92-9018-44CB-8D1C-D4CC10342A9D

P2093

Q34580316-09048EDC-50B2-45A5-8ECB-164C97A0414F

Q34580316-0D538A31-5A1A-4262-BD11-70B27A269755

Q34580316-15B32976-8733-4DBE-9E82-DAD494E18787

Q34580316-792DCE7D-FDAF-477A-915D-3B2BBBA69D5E

Q34580316-7CA10866-B289-4E6F-AB03-625DF1FE75F4

Q34580316-A0A75A25-1A0C-4D3A-A6BA-DA309E63EE6A

Q34580316-A24A977D-5DFA-4790-AD65-E08FA9EBC807

Q34580316-A9CCA967-C72F-4C3B-9050-0C551AEAD316

Q34580316-ABFAE7DD-3E2B-49EB-92B6-20BE633E7751

Q34580316-C552CE3C-492C-48EA-8B56-990F3260F587

P304

Q34580316-A834E1F2-5141-4F99-9707-1CA5D23F819A

P31

Q34580316-7C36A238-8FC8-4A44-8A74-1204EAE77162

P356

Q34580316-815AD723-8ABA-450D-A2B7-B05DE2654A9B

P407

Q34580316-C260DA92-A5D2-4727-BE38-B0D4A9EF94E4

P433

Q34580316-F45EF300-2F85-4F96-84EA-B23AB09C74F7

P478

Q34580316-ADBB0795-C12B-428E-8A2C-9C57322C16C0

P577

Q34580316-AB2A4C03-D81D-488E-A3D2-1AC2DE7819E1

P698

Q34580316-D56BBF3D-B9F0-462D-8EF9-E2278DBC5344

P356

P1433

The New England Journal of Medicine

P1476

Anidulafungin versus fluconazole for invasive candidiasis.

@en

P2093

Anidulafungin Study Group

http://www.w3.org/2001/XMLSchema#string

Annette C Reboli

http://www.w3.org/2001/XMLSchema#string

Beth P Goldstein

http://www.w3.org/2001/XMLSchema#string

Coleman Rotstein

http://www.w3.org/2001/XMLSchema#string

Daniel H Kett

http://www.w3.org/2001/XMLSchema#string

David S Krause

http://www.w3.org/2001/XMLSchema#string

Deepali Kumar

http://www.w3.org/2001/XMLSchema#string

Jennifer Schranz

http://www.w3.org/2001/XMLSchema#string

Michele Wible

http://www.w3.org/2001/XMLSchema#string

Peter G Pappas

http://www.w3.org/2001/XMLSchema#string

P304

2472-2482

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA066906

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

356

http://www.w3.org/2001/XMLSchema#string

P577

2007-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17568028

http://www.w3.org/2001/XMLSchema#string